a non-receptor tyrosine-kinase of the Jak family expressed predominantly in immune cells. Mediates signal transduction via the common gamma-chain of cytokine receptors, including IL-2, -4, -7, -9, and -15. Interacts with members of the STAT (signal transduction and activators of transcription) family. Interacts with STAM2 and SHB. Contains two protein kinase domains. Mutations that abrogate JAK3 function cause an autosomal SCID (severe combined immunodeficiency disease). Inhibitor: R017s for organ transplants. Three differentially spliced isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: Kinase, protein; EC 188.8.131.52; Protein kinase, TK; Protein kinase, tyrosine (non-receptor); TK group; JakA family
Cellular Component: extrinsic to internal side of plasma membrane; cytoskeleton; endomembrane system; cytosol
Molecular Function: protein binding; protein-tyrosine kinase activity; non-membrane spanning protein tyrosine kinase activity; protein phosphatase binding; ATP binding; hormone receptor binding
Biological Process: cell migration; negative regulation of interleukin-12 production; peptidyl-tyrosine phosphorylation; negative regulation of FasL biosynthetic process; negative regulation of interleukin-10 production; negative regulation of T-helper 1 cell differentiation; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; regulation of apoptosis; negative regulation of dendritic cell cytokine production; tyrosine phosphorylation of STAT protein; B cell differentiation; erythrocyte differentiation; innate immune response; positive regulation of transcription from RNA polymerase II promoter; T cell homeostasis; positive regulation of T cell proliferation; inflammatory response; negative regulation of T cell activation; transmembrane receptor protein tyrosine kinase signaling pathway; STAT protein nuclear translocation
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.